Literature DB >> 17594948

Molecular biology of cervical cancer.

A González Martín1.   

Abstract

Cervical cancer is a virus-induced disease that is caused by the integration of high-risk infecting human papillomaviruses (HPV) in the host genome. For this reason, the carcinogenesis process of cervical cancer is associated to the expression of the viral oncogenic proteins E6 and E7. These proteins are capable of inactivating p53 and pRb, which induces a continuous cell proliferation with the increasing risk of accumulation of DNA damage that eventually leads to cancer. Moreover, cervical cancer can be prevented by prophylactic HPV vaccines; their molecular characteristics and mechanism of action are reviewed. Ultimately, new molecular targets for cervical cancer like proteasome, the EGFR family and IGF family are exposed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594948     DOI: 10.1007/s12094-007-0066-8

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  54 in total

1.  The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth.

Authors:  A Brehm; S J Nielsen; E A Miska; D J McCance; J L Reid; A J Bannister; T Kouzarides
Journal:  EMBO J       Date:  1999-05-04       Impact factor: 11.598

2.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

Authors:  J B Sunwoo; Z Chen; G Dong; N Yeh; C Crowl Bancroft; E Sausville; J Adams; P Elliott; C Van Waes
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  Interaction of the bovine papillomavirus E2 protein with Brd4 tethers the viral DNA to host mitotic chromosomes.

Authors:  Jianxin You; Jennie L Croyle; Akiko Nishimura; Keiko Ozato; Peter M Howley
Journal:  Cell       Date:  2004-04-30       Impact factor: 41.582

Review 4.  Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer.

Authors:  Gary M Clifford; Rashida K Rana; Silvia Franceschi; Jennifer S Smith; Gerald Gough; Jeanne M Pimenta
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-05       Impact factor: 4.254

5.  Human papillomavirus types 16, 31, and 58 use different endocytosis pathways to enter cells.

Authors:  Latifa Bousarghin; Antoine Touzé; Pierre-Yves Sizaret; Pierre Coursaget
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

Review 6.  The insulin-like growth factor system and cancer.

Authors:  Derek LeRoith; Charles T Roberts
Journal:  Cancer Lett       Date:  2003-06-10       Impact factor: 8.679

7.  Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses.

Authors:  Alba-Lucia Combita; Antoine Touzé; Latifa Bousarghin; Neil D Christensen; Pierre Coursaget
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

8.  The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors.

Authors:  M J Antinore; M J Birrer; D Patel; L Nader; D J McCance
Journal:  EMBO J       Date:  1996-04-15       Impact factor: 11.598

Review 9.  Epigenetics of cervical cancer. An overview and therapeutic perspectives.

Authors:  Alfonso Dueñas-González; Marcela Lizano; Myrna Candelaria; Lucely Cetina; Claudia Arce; Eduardo Cervera
Journal:  Mol Cancer       Date:  2005-10-25       Impact factor: 27.401

10.  A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes.

Authors:  Pilar Zambrano; Blanca Segura-Pacheco; Enrique Perez-Cardenas; Lucely Cetina; Alma Revilla-Vazquez; Lucía Taja-Chayeb; Alma Chavez-Blanco; Enrique Angeles; Gustavo Cabrera; Karina Sandoval; Catalina Trejo-Becerril; Jose Chanona-Vilchis; Alfonso Duenas-González
Journal:  BMC Cancer       Date:  2005-04-29       Impact factor: 4.430

View more
  8 in total

1.  Naive and radiolabeled antibodies to E6 and E7 HPV-16 oncoproteins show pronounced antitumor activity in experimental cervical cancer.

Authors:  R Phaëton; J Gutierrez; Z Jiang; R G Karabakhtsian; J Albanese; J Sunkara; D R Fisher; G L Goldberg; E Dadachova
Journal:  Immunotherapy       Date:  2015-06-22       Impact factor: 4.196

2.  STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment.

Authors:  Lidia Santos Silva; Luis Gafeira Goncalves; Fernanda Silva; Germana Domingues; Valdemar Maximo; Joana Ferreira; Eric W-F Lam; Sergio Dias; Ana Felix; Jacinta Serpa
Journal:  Tumour Biol       Date:  2015-11-12

Review 3.  Potential mechanisms of the human polyomavirus JC in neural oncogenesis.

Authors:  Luis Del Valle; Martyn K White; Kamel Khalili
Journal:  J Neuropathol Exp Neurol       Date:  2008-08       Impact factor: 3.685

4.  Antiviral activity of Bifidobacterium adolescentis SPM1005-A on human papillomavirus type 16.

Authors:  Min-Kyeong Cha; Do-Kyung Lee; Hyang-Mi An; Si-Won Lee; Seon-Hee Shin; Jeong-Hyun Kwon; Kyung-Jae Kim; Nam-Joo Ha
Journal:  BMC Med       Date:  2012-07-12       Impact factor: 8.775

5.  Transcriptional regulation of E-cadherin and oncoprotein E7 by valproic acid in HPV positive cell lines.

Authors:  Ebrahim Faghihloo; Abolfazl Akbari; Fatemeh Adjaminezhad-Fard; Talat Mokhtari-Azad
Journal:  Iran J Basic Med Sci       Date:  2016-06       Impact factor: 2.699

6.  HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors.

Authors:  Olga Martinho; Renato Silva-Oliveira; Fernanda P Cury; Ana Martins Barbosa; Sara Granja; Adriane Feijó Evangelista; Fábio Marques; Vera Miranda-Gonçalves; Diana Cardoso-Carneiro; Flávia E de Paula; Maicon Zanon; Cristovam Scapulatempo-Neto; Marise A R Moreira; Fátima Baltazar; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  Theranostics       Date:  2017-01-15       Impact factor: 11.556

7.  RKIP inhibition in cervical cancer is associated with higher tumor aggressive behavior and resistance to cisplatin therapy.

Authors:  Olga Martinho; Filipe Pinto; Sara Granja; Vera Miranda-Gonçalves; Marise A R Moreira; Luis F J Ribeiro; Celso di Loreto; Marsha R Rosner; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

8.  Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo.

Authors:  Małgorzata Sekuła; Katarzyna Miekus; Marcin Majka
Journal:  Int J Oncol       Date:  2014-04-11       Impact factor: 5.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.